{"id":"https://openalex.org/W2092015313","doi":"https://doi.org/10.3111/13696998.2015.1029492","title":"Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-na\u00efve chronic hepatitis C genotype 1 patients in Japan","display_name":"Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-na\u00efve chronic hepatitis C genotype 1 patients in Japan","publication_year":2015,"publication_date":"2015-03-12","ids":{"openalex":"https://openalex.org/W2092015313","doi":"https://doi.org/10.3111/13696998.2015.1029492","mag":"2092015313","pmid":"https://pubmed.ncbi.nlm.nih.gov/25763827"},"language":"en","primary_location":{"id":"doi:10.3111/13696998.2015.1029492","doi":"https://doi.org/10.3111/13696998.2015.1029492","is_oa":true,"landing_page_url":"https://doi.org/10.3111/13696998.2015.1029492","pdf_url":"https://www.tandfonline.com/doi/pdf/10.3111/13696998.2015.1029492?needAccess=true","source":{"id":"https://openalex.org/S155267287","display_name":"Journal of Medical Economics","issn_l":"1369-6998","issn":["1369-6998","1941-837X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320449","host_organization_name":"Informa","host_organization_lineage":["https://openalex.org/P4310320449"],"host_organization_lineage_names":["Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medical Economics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://www.tandfonline.com/doi/pdf/10.3111/13696998.2015.1029492?needAccess=true","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5083566499","display_name":"Hiroyo Kuwabara","orcid":"https://orcid.org/0000-0001-6086-6453","observed_orcids":["https://orcid.org/0000-0001-6086-6453"]},"institutions":[{"id":"https://openalex.org/I4405265673","display_name":"Janssen Pharmaceutical K.K. (Japan)","ror":"https://ror.org/05eqqvk78","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405265673"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hiroyo Kuwabara","raw_affiliation_strings":["Janssen Pharmaceutical KK , Tokyo , Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Pharmaceutical KK , Tokyo , Japan","institution_ids":["https://openalex.org/I4405265673"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110180262","display_name":"K.Y. Westerhout","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210094451","display_name":"Pharmerit (Netherlands)","ror":"https://ror.org/00ntr9f13","country_code":"NL","type":"company","lineage":["https://openalex.org/I4210094451","https://openalex.org/I4210134090"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Kirsten Westerhout","raw_affiliation_strings":["Pharmerit BV, Rotterdam, the Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmerit BV, Rotterdam, the Netherlands","institution_ids":["https://openalex.org/I4210094451"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108542558","display_name":"M. Treur","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210094451","display_name":"Pharmerit (Netherlands)","ror":"https://ror.org/00ntr9f13","country_code":"NL","type":"company","lineage":["https://openalex.org/I4210094451","https://openalex.org/I4210134090"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Maarten Treur","raw_affiliation_strings":["Pharmerit BV, Rotterdam, the Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmerit BV, Rotterdam, the Netherlands","institution_ids":["https://openalex.org/I4210094451"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037637505","display_name":"Karin H. Cerri","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]},{"id":"https://openalex.org/I909854389","display_name":"London School of Economics and Political Science","ror":"https://ror.org/0090zs177","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I909854389"]}],"countries":["BE","GB"],"is_corresponding":false,"raw_author_name":"Karin Cerri","raw_affiliation_strings":["Janssen Pharmaceutica NV, Beerse, Belgium, and London School of Economics and Political Sciences, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Pharmaceutica NV, Beerse, Belgium, and London School of Economics and Political Sciences, London, UK","institution_ids":["https://openalex.org/I137982388","https://openalex.org/I909854389"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088342461","display_name":"J\u00f6rg Mahlich","orcid":"https://orcid.org/0000-0003-1110-2793","observed_orcids":["https://orcid.org/0000-0003-1110-2793"]},"institutions":[{"id":"https://openalex.org/I44260953","display_name":"Heinrich Heine University D\u00fcsseldorf","ror":"https://ror.org/024z2rq82","country_code":"DE","type":"education","lineage":["https://openalex.org/I44260953"]}],"countries":["DE"],"is_corresponding":true,"raw_author_name":"Joerg Mahlich","raw_affiliation_strings":["Janssen Pharmaceutical KK, Tokyo, Japan, and Institute of Competition Economics (DICE), University of D\u00fcsseldorf, D\u00fcsseldorf, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Pharmaceutical KK, Tokyo, Japan, and Institute of Competition Economics (DICE), University of D\u00fcsseldorf, D\u00fcsseldorf, Germany","institution_ids":["https://openalex.org/I44260953"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5060414282","display_name":"Hiroshi Yatsuhashi","orcid":"https://orcid.org/0000-0001-5487-3403","observed_orcids":["https://orcid.org/0000-0001-5487-3403"]},"institutions":[{"id":"https://openalex.org/I4210118695","display_name":"Nagasaki Medical Center","ror":"https://ror.org/02qv90y91","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210118695","https://openalex.org/I4210137409"]},{"id":"https://openalex.org/I4210137409","display_name":"National Hospital Organization","ror":"https://ror.org/03ntccx93","country_code":"JP","type":"government","lineage":["https://openalex.org/I4210137409"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hiroshi Yatsuhashi","raw_affiliation_strings":["National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan","institution_ids":["https://openalex.org/I4210118695","https://openalex.org/I4210137409"]}]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":7,"corresponding_author_ids":["https://openalex.org/A5088342461"],"corresponding_institution_ids":["https://openalex.org/I44260953"],"apc_list":null,"apc_paid":null,"fwci":1.9428,"has_fulltext":true,"cited_by_count":14,"citation_normalized_percentile":{"value":0.85836984,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":98},"biblio":{"volume":"18","issue":"7","first_page":"502","last_page":"511"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10151","display_name":"Hepatitis C virus research","score":0.9199000000953674,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10151","display_name":"Hepatitis C virus research","score":0.9199000000953674,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.0786999985575676,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/simeprevir","display_name":"simeprevir","score":0.9990000128746033},{"id":"https://openalex.org/keywords/chronic-hepatitis-c","display_name":"chronic hepatitis C","score":0.9390000104904175},{"id":"https://openalex.org/keywords/hcv-genotype-1","display_name":"HCV genotype 1","score":0.9160000085830688},{"id":"https://openalex.org/keywords/pegylated-interferon","display_name":"pegylated interferon","score":0.7929999828338623},{"id":"https://openalex.org/keywords/ribavirin","display_name":"ribavirin","score":1.0},{"id":"https://openalex.org/keywords/telaprevir","display_name":"telaprevir","score":0.8920000195503235},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.7379999756813049},{"id":"https://openalex.org/keywords/triple-therapy","display_name":"triple therapy","score":0.7319999933242798},{"id":"https://openalex.org/keywords/protease-inhibitors","display_name":"protease inhibitors","score":0.7749999761581421},{"id":"https://openalex.org/keywords/treatment-naive-patients","display_name":"treatment-naive patients","score":0.8320000171661377},{"id":"https://openalex.org/keywords/markov-model","display_name":"Markov model","score":0.8009999990463257},{"id":"https://openalex.org/keywords/life-years","display_name":"life-years","score":0.6060000061988831},{"id":"https://openalex.org/keywords/health-care-costs","display_name":"health care costs","score":0.7699999809265137},{"id":"https://openalex.org/keywords/sustained-virologic-response","display_name":"sustained virological response","score":0.8489999771118164},{"id":"https://openalex.org/keywords/japan","display_name":"Japan","score":0.7519999742507935}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8936078548431396},{"id":"https://openalex.org/C2778986448","wikidata":"https://www.wikidata.org/wiki/Q7517689","display_name":"Simeprevir","level":5,"score":0.8648287057876587},{"id":"https://openalex.org/C2778159067","wikidata":"https://www.wikidata.org/wiki/Q408557","display_name":"Telaprevir","level":5,"score":0.7306263446807861},{"id":"https://openalex.org/C2780040827","wikidata":"https://www.wikidata.org/wiki/Q421862","display_name":"Ribavirin","level":4,"score":0.654948353767395},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5826559066772461},{"id":"https://openalex.org/C2778390639","wikidata":"https://www.wikidata.org/wiki/Q2502747","display_name":"Sofosbuvir","level":5,"score":0.5391886830329895},{"id":"https://openalex.org/C2776455275","wikidata":"https://www.wikidata.org/wiki/Q154869","display_name":"Hepatitis C","level":2,"score":0.511323869228363},{"id":"https://openalex.org/C3020491458","wikidata":"https://www.wikidata.org/wiki/Q131742","display_name":"Chronic hepatitis","level":3,"score":0.446809858083725},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.41792580485343933},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.19599804282188416},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.0},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000069616","descriptor_name":"Simeprevir","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D000069616","descriptor_name":"Simeprevir","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007372","descriptor_name":"Interferons","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D007372","descriptor_name":"Interferons","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D007564","descriptor_name":"Japan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008390","descriptor_name":"Markov Chains","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010641","descriptor_name":"Phenotype","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012254","descriptor_name":"Ribavirin","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D012254","descriptor_name":"Ribavirin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D015201","descriptor_name":"Meta-Analysis as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017059","descriptor_name":"Models, Econometric","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018450","descriptor_name":"Disease Progression","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019698","descriptor_name":"Hepatitis C, Chronic","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D019698","descriptor_name":"Hepatitis C, Chronic","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D019698","descriptor_name":"Hepatitis C, Chronic","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.3111/13696998.2015.1029492","doi":"https://doi.org/10.3111/13696998.2015.1029492","is_oa":true,"landing_page_url":"https://doi.org/10.3111/13696998.2015.1029492","pdf_url":"https://www.tandfonline.com/doi/pdf/10.3111/13696998.2015.1029492?needAccess=true","source":{"id":"https://openalex.org/S155267287","display_name":"Journal of Medical Economics","issn_l":"1369-6998","issn":["1369-6998","1941-837X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320449","host_organization_name":"Informa","host_organization_lineage":["https://openalex.org/P4310320449"],"host_organization_lineage_names":["Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medical Economics","raw_type":"journal-article"},{"id":"pmid:25763827","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25763827","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of medical economics","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.3111/13696998.2015.1029492","doi":"https://doi.org/10.3111/13696998.2015.1029492","is_oa":true,"landing_page_url":"https://doi.org/10.3111/13696998.2015.1029492","pdf_url":"https://www.tandfonline.com/doi/pdf/10.3111/13696998.2015.1029492?needAccess=true","source":{"id":"https://openalex.org/S155267287","display_name":"Journal of Medical Economics","issn_l":"1369-6998","issn":["1369-6998","1941-837X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320449","host_organization_name":"Informa","host_organization_lineage":["https://openalex.org/P4310320449"],"host_organization_lineage_names":["Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medical Economics","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2092015313.pdf","grobid_xml":"https://content.openalex.org/works/W2092015313.grobid-xml"},"referenced_works_count":29,"referenced_works":["https://openalex.org/W1510386142","https://openalex.org/W1945909195","https://openalex.org/W1978892007","https://openalex.org/W1984413237","https://openalex.org/W1984863107","https://openalex.org/W1987584200","https://openalex.org/W2002345728","https://openalex.org/W2022693941","https://openalex.org/W2026828547","https://openalex.org/W2041643208","https://openalex.org/W2042069958","https://openalex.org/W2044287878","https://openalex.org/W2060263975","https://openalex.org/W2064551064","https://openalex.org/W2068790832","https://openalex.org/W2084417858","https://openalex.org/W2087749147","https://openalex.org/W2091664007","https://openalex.org/W2099748512","https://openalex.org/W2106922189","https://openalex.org/W2125963799","https://openalex.org/W2143093568","https://openalex.org/W2143244227","https://openalex.org/W2161019027","https://openalex.org/W2163731183","https://openalex.org/W2299516344","https://openalex.org/W2398872043","https://openalex.org/W2402529736","https://openalex.org/W4285719527"],"related_works":["https://openalex.org/W2011880652","https://openalex.org/W1993580270","https://openalex.org/W4248230003","https://openalex.org/W2189194747","https://openalex.org/W1891391480","https://openalex.org/W1945909195","https://openalex.org/W2087291119","https://openalex.org/W2073830953","https://openalex.org/W2317638828","https://openalex.org/W2334551942"],"abstract_inverted_index":{"AIM:":[0],"Simeprevir":[1],"(SMV),":[2],"a":[3,103,164,180],"protease":[4],"inhibitor,":[5],"recently":[6],"became":[7],"available":[8],"for":[9,245],"the":[10,38,46,77,86,153,204,218,240],"treatment":[11,63,166,243],"of":[12,24,48,81,206,220],"chronic":[13],"hepatitis":[14],"C":[15],"(HCV)":[16],"genotype":[17,248],"1":[18,249],"patients":[19,66,250],"in":[20,29,64,67,111,201,203,251],"Japan.":[21,68,112,252],"The":[22,41,194,211],"introduction":[23],"triple":[25],"therapy":[26],"using":[27],"SMV":[28,49],"combination":[30],"with":[31,50,56,208],"peginterferon":[32],"and":[33,83,90,123,143,176,185,190],"ribavirin":[34],"(PR)":[35],"significantly":[36],"improves":[37],"cure":[39],"rate.":[40],"aim":[42],"was":[43,73,160,224],"to":[44,54,75,84,151,162,188,198,232,238],"assess":[45,152],"cost-effectiveness":[47,136],"PR":[51,57,59,191,209],"(SMV/PR)":[52],"compared":[53,187],"telaprevir":[55],"(TVR/PR),":[58],"alone,":[60,192],"or":[61],"no":[62],"treatment-na\u00efve":[65,246],"METHODS:":[69],"A":[70],"Markov":[71],"model":[72,156],"developed":[74],"reflect":[76],"natural":[78],"disease":[79],"progression":[80,117],"HCV":[82,116,247],"estimate":[85],"average":[87],"life":[88,144,170],"years":[89,171,178],"lifetime":[91],"healthcare":[92],"costs":[93,125],"per":[94],"patient.":[95],"Sustained":[96],"virologic":[97],"response":[98],"rates":[99],"were":[100,126,132,149,172,196],"obtained":[101,127],"from":[102,128],"network":[104],"meta-analysis":[105],"including":[106],"randomized":[107],"clinical":[108],"trials":[109],"conducted":[110,150],"Patient":[113],"baseline":[114],"characteristics,":[115],"rates,":[118],"mortality,":[119],"medical":[120],"resource":[121],"utilization,":[122],"unit":[124],"Japanese":[129],"sources.":[130],"Outcomes":[131],"reported":[133],"as":[134,138,140,168],"incremental":[135,141],"ratios":[137],"well":[139],"cost":[142,182],"years.":[145],"Various":[146],"sensitivity":[147,199,214],"analyses":[148,215],"uncertainty":[154],"around":[155],"outcomes.":[157],"RESULTS:":[158],"SMV/PR":[159,207,221,235],"estimated":[161,237],"be":[163,239],"cost-effective":[165,223,242],"option":[167],"more":[169],"gained":[173],"by":[174,183],"0.235":[175],"0.873":[177],"at":[179,227,229],"reduced":[181],"\u00a5263,037":[184],"\u00a5776,900":[186],"TVR/PR":[189],"respectively.":[193],"results":[195],"robust":[197],"analyses,":[200],"particular":[202],"comparison":[205],"alone.":[210],"multivariate":[212],"probabilistic":[213],"showed":[216],"that":[217],"probability":[219],"being":[222],"relatively":[225],"constant":[226],"\u223c87%":[228],"any":[230],"willingness":[231],"pay.":[233],"CONCLUSIONS:":[234],"is":[236],"most":[241],"strategy":[244]},"counts_by_year":[{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":3}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2016-06-24T00:00:00"}